When you get the right people working together and engaged in the right subjects, it is the formula for accelerating change within the industry. This is what has been developed within the Cell and Gene Therapy phorum in the build up to their second face-to-face meeting in Texas on 14-15 November 2018.
Since its launch, the Phorum has brought 14 member companies together to mobilize six workstreams which are focusing on key pre-competition areas: high level analytics, regulatory strategy, commercialization, validation, raw material sourcing and supply, and environmental health and safety.
The forthcoming meeting will focus on regulatory strategy and high level analytics as well as a tour of the FujiFilm Diosynth facility in College Station, Texas. Over 70 subject matter experts are committed to working together to engage with external agencies and regulators. This will ensure the industry accelerates to address these pressure points in this rapidly developing arena.
The business of cell and gene therapy is as diverse as the patients which it serves and for that there is no one size fits all solution. It is because of the visionaries within this arena that the creativity has been able to flourish. Creating a collaboration that works alongside this and ensuring robust participation from all members will be the driving force behind achieving the Phorum’s goals.
Member companies anticipate that this new Phorum will provide a full awareness of the market place, an understanding of new innovations within the field, an ability to share capabilities and offerings, technological advances and benchmarking across the industry.
Members of the Cell and Gene Therapy Phorum are: Aldevron, Amgen, AstraZeneca, Bayer, Biogen, BioMarin, bluebird bio, Fujifilm Diosynth, Janssen, Juno, Lonza, MilliporeSigma, Roche and Sanofi.
Please contact Christelle Simpson-Platre on email@example.com if you would like to learn more, or would like to become involved.